Latest news with #DavinthraThillainathan
Business Insider
23-05-2025
- Business
- Business Insider
Goldman Sachs Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (RMD – Research Report) on May 20 and set a price target of A$49.30. The company's shares closed today at A$38.24. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thillainathan covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, CSL, and Cochlear . According to TipRanks, Thillainathan has an average return of 3.7% and a 75.00% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per with a A$44.69 average price target.
Business Insider
22-05-2025
- Business
- Business Insider
Ramsay Health Care (RMSYF) Receives a Hold from Goldman Sachs
Goldman Sachs analyst Davinthra Thillainathan maintained a Hold rating on Ramsay Health Care (RMSYF – Research Report) on May 19 and set a price target of A$39.00. The company's shares closed last Thursday at $22.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Thillainathan covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, CSL, and Cochlear . According to TipRanks, Thillainathan has an average return of 1.6% and a 63.64% success rate on recommended stocks. Currently, the analyst consensus on Ramsay Health Care is a Hold with an average price target of $25.22, which is a 14.64% upside from current levels. In a report released on May 16, Morgan Stanley also maintained a Hold rating on the stock with a A$37.20 price target.
